142 related articles for article (PubMed ID: 20683173)
1. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Endocr J; 2010; 57(9):777-86. PubMed ID: 20683173
[TBL] [Abstract][Full Text] [Related]
2. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
[TBL] [Abstract][Full Text] [Related]
3. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Palumbo I; Randazzo S; Cicero AF
Intern Med; 2010; 49(16):1717-25. PubMed ID: 20720348
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
[TBL] [Abstract][Full Text] [Related]
5. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
[TBL] [Abstract][Full Text] [Related]
6. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
[TBL] [Abstract][Full Text] [Related]
7. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Palumbo I; Randazzo S; Cicero AF
Metabolism; 2011 Mar; 60(3):421-9. PubMed ID: 20423740
[TBL] [Abstract][Full Text] [Related]
9. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
[TBL] [Abstract][Full Text] [Related]
10. Exenatide versus glibenclamide in patients with diabetes.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
[TBL] [Abstract][Full Text] [Related]
13. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
[TBL] [Abstract][Full Text] [Related]
15. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
18. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
19. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
[TBL] [Abstract][Full Text] [Related]
20. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
